Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GlobeStar Therapeutics Corporation (GSTC)
Richland, WA, US
GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing proprietary drug formulations. These innovative treatments specifically target multiple sclerosis (MS) and various other neurodegenerative disorders. Established in 2016, the company was formerly known as AngioSoma, Inc., rebranding to GlobeStar Therapeutics Corporation in July 2021. Its operations are headquartered in Richland, Washington.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +9,900.00% | +9,900.00% | +0.00% | -97.37% | -99.79% | -99.88% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+0.0% Q2'24: +86.7% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q2'24: +59.6% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+31.6% Q2'24: +43.3% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×54.43× Q2'24: 230.43× (vs Q2'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-03 | KATZAROFF JAMES C | Director / Officer | J-Other | A | Common stock | 70,422,535 | 0.01 | 500.0K | 80,422,535 | — | ↗ |
| 2023-02-24 | KATZAROFF JAMES C | Director / Officer | A-Award | A | Options | 35,000,000 | 0.01 | 315.0K | 65,000,000 | — | ↗ |
| 2022-11-23 | Chicoski Robert | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 3,041,721 | — | ↗ |
| 2021-05-12 | KATZAROFF JAMES C | Director / Officer | A-Award | A | Options | 30,000,000 | 0.03 | 900.0K | 30,000,000 | — | ↗ |
| 2021-02-10 | Chicoski Robert | Officer | — | D | COMMON STOCK | 0 | 0.00 | — | 4,000,000 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2018 | Alex K. Blankenship Chairman and Chief Executive Officer | 45.0K | — | — | — | — | 5.5K | 50.5K | 0.00% | ↗ |
| 2 | 2017 | Alex K. Blankenship Chairman and Chief Executive Officer | — | — | 24.0K | — | — | — | 24.0K | 100.00% | ↗ |
| 3 | 2014 | G. Jonathan Piña Former CEO | 110.0K | — | — | — | — | — | 105.0K | 0.00% | ↗ |
| 4 | 2014 | Robert Federowicz Former interim CEO | 21.7K | — | — | — | — | — | 21.7K | 0.00% | ↗ |
| 5 | 2013 | Harvey Bryant Former CEO | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 6 | 2013 | G. Jonathan Piña Former CEO | 62.2K | — | — | — | — | — | 62.2K | 0.00% | ↗ |
| 7 | 2013 | Robert Federowicz Former interim CEO | 25.0K | — | — | — | — | — | 25.0K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James C. Katzaroff | President, Chief Executive Officer, Secretary, Principal Executive Officer & Chairman of the Board | 180.0K | male |
| Brooke Greenwald | Chief Marketing Officer | — | female |
| David Croom | Executive Vice President | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GSTC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
